PRNewsWire
10 Sept 2026, 23:20 UTC · 9h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
Tyra Biosciences' Phase 2 SURF302 study results showed Grade 3 treatment-emergent adverse events in 14% and 9% of the 60 mg and 50 mg dose cohorts, respectively. — High rates of severe adverse events in a Phase 2 trial increase the risk of clinical failure or regulatory rejection for the drug candidate.
-0.60Pomerantz LLP has launched an investigation into Tyra Biosciences for potential securities fraud or unlawful business practices following the SURF302 data release. — The threat of class-action litigation creates legal overhang and potential financial liabilities for the company.
-0.40Tyra Biosciences' stock price dropped 17.66% to $22.01 per share on September 9, 2026, following the SURF302 announcement. — The price action confirms immediate market disappointment and a loss of investor confidence in the asset's value.
-0.20Which stocks this story touches
Continue reading
5 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
1h ago
